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A 77-year-old man was admitted to the Intensive Care 
Unit (ICU) for an acute subarachnoid hemorrhage. His 
recent medical history included a diagnosis of culture 
negative brain abscess treated with a combination ther-
apy of linezolid and meropenem six weeks prior to ICU 
admission. The patient underwent neurosurgery and 
mechanical ventilation was started. During the early 
post-operative period the patient had an acute worsen-
ing of respiratory gas exchanges, associated with leu-
kocytosis. Chest radiography showed left pneumonia 
and tracheal aspirate was positive for Extended Spec-
trum Beta Lactamases (ESBL)-producing E. coli. Thus, 
therapy with meropenem 1 g every 8 hours was started, 
with improvement of clinical conditions. However, af-
ter 12 days after intubation the patient developed fever 
and hypotension with sudden worsening of respiratory 
gases and metabolic acidosis. A CT scan of the chest 
revealed bilateral multiple areas of consolidation of the 
lungs. Bronchoalveolar lavage culture was positive for 
colistin- (COL) and carbapenem-resistant Acinetobacter 
baumannii and methicillin-resistant S. aureus (MRSA). 
Meropenem was discontinuated and therapy with i.v. 
colistin 9.000.000 UI loading dose followed by 4.500.000 
UI every 12 hours plus rifampin (RIF) 600 mg/day plus 
vancomycin (VAN) 1g loading dose followed by 2 g/day 
was initiated. Aerosolized COL (1.000.000 UI every 8 
hours) was also administered. The clinical conditions 
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in creatinine level was observed (up to 3 mg/dL), lead-
ing to the reduction of COL dosages to 2.500.000 ev-
ery 12 hours and discontinuation of VAN after 6 days 
of therapy. Serum bactericidal activity (SBA) performed 
at day 3 of therapy was 1:16 (pre-dose) and 1:64 (after 
dose). COL and RIF were stopped after 2 weeks of ther-
apy, with resolution of the infection and progressive im-
provement of renal function after 4 weeks. The patient 
was then transferred to a rehabilitation center 7 weeks 
after ICU admission. 
Considering its challenging antimicrobial susceptibility 
pattern, the clinical isolate was immediately submitted 
to additional in vitro analyses including synergy testing 
by both checkerboard method and killing tests.
Minimal inhibitory concentrations (MICs) of COL, VAN 
and RIF were determined by broth macrodilution method 
(BMD) in cation-adjusted Mueller Hinton broth (CAM-
HB) (CLSI, 2012). Furthermore, for COL MIC determina-
tion a gradient strip test (E-test) was used. Synergy tests 
were performed throughout the checkerboard method 
at different concentrations of COL+RIF, COL+VAN and 
COL+RIF+VAN combinations. Complete synergism was 
defined as FIC-index (FICI) ≤0.5. The activity of COL, 
VAN and RIF, alone and in combination, was also inves-
tigated by time-kill studies at a final inoculum of ~5x105 
CFU/ml at the following concentrations: 1xMIC COL, 
0.25xMIC VAN, 1xMIC RIF, 1xMIC COL+0.25xMIC VAN, 
1xMIC COL+1xMIC RIF, 1xMIC COL+0.25xMIC VAN+ 
1xMIC RIF. The VAN concentration used for killing stud-
ies reflected the serum trough level achieved during ther-
apy (16 mg/L). Bactericidal activity was defined as ≥3-
log10 CFU/ml reduction of the initial bacterial count at 
each time point whereas synergistic activity was defined 
as a ≥100-fold decrease in CFU/mL between the combi-
nation and its most active constituent at the same con-
centration after 24 h. The detection limit was 10 CFU/
mL. SBA was determined at 3th day of COL+VAN+RIF 
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SUMMARY
We present the case of a patient with ventilator-associated pneumonia (VAP) caused by a pan-resistant 
Acinetobacter baumannii successfully treated with the combination colistin plus vancomycin plus rifamp-
in, whose in vitro activity was investigated by checkerboard method and killing testing. Furthermore, the 
serum bactericidal activity (SBA) was assessed. 
Our case shows that an innovative regimen consisting of colistin plus antimicrobials active only against 
Gram-positive microorganisms might represent a valid therapeutic option for severe infections caused by 
colistin-resistant A. baumannii.
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therapy by collecting patient’s blood 30 min before and 2 
h after therapy administration.
Throughout MBD, MICs of COL, RIF and VAN were 
4, 2 and 64 mg/L, respectively. By using E-test, COL 
MIC was 4 mg/L. A complete synergism was observed 
for COL+VAN and COL+RIF. At killing experiments, 
COL (1xMIC, 4 mg/L) and RIF (1xMIC, 2 mg/L) alone 
showed only a slight decrease of CFU/mL whereas VAN 
(0.25xMIC, 16 mg/L) alone did not have any effect on 
lowering the bacterial growth (Figure 1). On the oth-
er hand, when the combinations COL+VAN, COL+RIF 
and COL+VAN+RIF were tested, a rapid bactericidal 
activity was observed after 2 h. All tested combinations 
showed an absence of growth at 6h, which was main-
tained up to 24 h. In particular, absence of growth was 
observed at 6 h for COL+RIF combination whereas 
COL+VAN and COL+VAN+RIF yielded no bacteria at 
4 h and 2 h, respectively. All the tested combinations 
were synergic at 24 h.
Infections caused by A. baumannii are associated with a 
high mortality rate especially in the presence of multi-
drug resistant (MDR) strains since therapeutic options 
are severely limited (Maragakis et al., 2008; Orsi et al., 
2011). Colistin-based combinations have been consid-
ered the milestone of the treatment of MDR A. bauman-
ni (Motaouakkil et al., 2006; Durante-Mangoni et al., 
2013) whereas unconventional regimens against carbap-
enem-resistant A. baumannii include the combination 
of COL plus rifampin (RIF) or glycopeptides (Garna-
cho-Montero et al., 2013; Petrosillo et al., 2014; Ceccarelli 
et al., 2015). However, the emergence of COL resistance 
represents a real challenge and nowadays insufficient 
data are available for the treatment of A. baumannii in-
fections due to COL-resistant strains (Leite et al., 2016).
In the present case, we demonstrated that a regimen con-
sisting of COL plus antimicrobials active only against 
Gram-positive microorganisms might represent a val-
id therapeutic option for severe infections caused by 
COL-resistant A. baumannii. The observed clinical effec-
tiveness was confirmed by both SBA (performed at the 3rd 
day of COL+VAN+RIF therapy) and killing studies, which 
showed a high and early bactericidal activity for all the 
tested combinations. Interestingly, COL+VAN was more 
rapid in reducing the bacterial load than COL+RIF, which 
has hitherto been considered a primary regimen against 
carbapenem-resistant A. baumannii (Durante-Mango-
ni et al., 2013). The rationale of using COL+VAN or RIF 
is based on the cell-permeabilizing properties of COL, 
which might allow the other drug to reach its target at in-
hibitory concentrations (Gordon et al., 2010; Vidaillac et 
al., 2012). Although preliminary in vitro data confirmed 
this effect even in the presence of COL resistance (Vid-
aillac et al., 2012; O’Hara et al., 2013; Bae et al., 2016), 
the clinical experience is still limited. Thus, the favorable 
result of combined clinical and microbiological data in 
the present case might be of crucial importance for the 
treatment of severe infections caused by colistin-resis-
tant A. baumannii.
Given that both A. baumannii and MRSA were isolated 
from the patient’s bronchoalveolar lavage, we should 
consider that the use of VAN and RIF as part of triple 
therapy against A. baumannii might also have had a role 
in the containment of S. aureus infection.
One of the major concerns regarding the combination 
COL+VAN resides in its potential nephrotoxicity. Al-
though data are still controversial (Garnacho-Montero et 
al., 2013; Petrosillo et al., 2014), our case confirms the 
potential toxicity of this regimen and we were forced to 
reduce colistin dosages and to discontinuate VAN after 6 
days of therapy. This latter aspect should be considered, 
especially if concomitant multiple nephrotoxic drugs 
are administered. If renal failure is a major concern, the 
combination COL+RIF is also highly effective, as con-
firmed by the in vitro experiments showing a rapid and 
durable antibacterial killing.
In conclusion, the results of our study suggest that 
COL, VAN and RIF used in different combinations 
might confer a therapeutic benefit in the treatment of 
severe infections caused by MDR A. baumannii, even in 
the presence of COL-resistant strains. Furthermore, we 
highlight the importance of performing in vitro synergy 
analyses, in order to guide treatment decisions and pre-
dict the potential efficacy of the selected antimicrobial 
combination.
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